Our interactive booth will let you discover our latest innovations within the range of diagnostic test kits and automation. Given the circumstances, one of our highlights will be the introduction of a comprehensive, AOAC PTM accredited workflow for SARS-CoV-2 detection on environmental surfaces. Regarding the „traditional” food and environmental testing solutions, we will introduce you to new products in the fields of allergen detection, mycotoxin analysis, GMO screening and glyphosate testing.
Eurofins GeneScan Technologies announces that the VIRSeek SARS-CoV-2 Solution has been evaluated and approved by the AOAC Performance Tested MethodsSM (PTM) Program on December 29, 2020 and awarded Emergency Response Validation PTM certification number 122006. The VIRSeek SARS-CoV-2 Solution is a comprehensive workflow for the detection of SARS-CoV-2 on environmental surfaces that includes swabbing of environmental surfaces, RNA extraction, analysis by Reverse Transcription PCR (RT-PCR) and evaluation by an advanced algorithm.
Eurofins Technologies, a supplier of test kits and systems for laboratory analyses, announces the launch of the new SENSIStrip Allergen product range, which quickly detects allergens that must be labeled on packaged food products.
Managing food allergies usually means completely eliminating the allergen from one’s diet. To achieve this, consumers rely on clear labeling and traceability throughout the entire food production process, from raw material to the final product.
SENSIStrip Allergen kits are based on the concept of an immunoassay, an easy-to-use and quick method that requires only a few minutes of incubation time. This enables adequate allergen control at different stages of the food manufacturing process, across food matrices, rinse water and equipment.
Eurofins Technologies announces the launch of two important products to support the fight against COVID-19:
• a CE-IVD labelled rapid test for the detection of SARS-CoV-2 antigens in 15 minutes; and
• a SARS-CoV-2 RT-PCR test that has been successfully validated for pharynx gargling samples, providing a gold standard PCR test in an easy-to-use, self-sampling format especially beneficial in the testing of children.
The GSD NovaGen SARS-CoV-2 (COVID-19) antigen rapid test provides results from nasopharyngeal samples within 15 minutes. With diagnostic sensitivity of 92.6% and diagnostic specificity of 98.6%, the test meets WHO performance criteria (sensitivity ≥ 80%; specificity ≥ 97%) for use in the global fight against COVID-19.
The Celer® ELISA kits, designed for the quantitative detection of a range of different mycotoxins, are now validated on the automated ELISA system The BoltTM to suit the diverse in-house testing needs of customers in the food, feed and agricultural industries. The BoltTM system is computer-controlled and capable of automating fluid handling, plate mixing, incubation timing, optical reading, calculations and report generation. It is possible to run sessions simultaneously with multiple Celer® kits to analyse up to 4 different parameters. Download this flyer for the available applications of validated mycotoxin assays.
The current world-wide increase in SARS-CoV-2 infections pushes qRT-PCR testing capacities to their limits. The GSD NovaPrime® SARS-CoV-2 Mplex FLA (Sanger) kit launched today by Eurofins Technologies utilizes the well-established Fragment Length Analysis principle on Sanger sequencing instruments (e.g. ABI 3730xl). There are a very large number of such instruments installed worldwide and this launch can significantly boost high throughput capacities of highly sensitive tests beyond what is available for qRT-PCR systems. This assay enables each ABI 3730xl sequencer to process more than 2,000 samples per day. This new kit also provides sensitivity and time to results similar to qRT-PCR testing.
This year analytica 2020, the largest trade show for lab technology, analysis, and biotechnology is going virtual! Analytica virtual will take place from October 19th to the 23rd, presenting hundreds of virtual booths, inspiring webinars and lectures available around the clock.
Eurofins Technologies will be participating with a virtual booth, along with 320 other companies in this exciting new format. We are looking forward to presenting our latest products and to connect with valuable business contacts.
We realize that a virtual fair does not allow a personal meeting or a hands-on experience with our products and instruments. However, the virtual booth frees you to explore our innovative solutions at your convenience. Explore our virtual booth, download our brochures, watch our product videos and send us a request for more information. Registration is free so sign up today at analytica virtual: free registration
Eurofins Technologies, a supplier of test kits and systems for laboratory analyses, announces the launch of its SENSISpec Soy Total protein ELISA kit, an enzyme immunoassay for the quantitative detection of soy protein in food and swab samples.
The development of the assay has been performed by Eurofins Immunolab, a biotechnology company with a wide experience in food allergen analysis and part of Eurofins Technologies group.
Soy is one of the “Big Eight” allergens, along with cow’s milk, eggs, peanuts, tree nuts, wheat, fish, and shellfish. These are responsible for 90 percent of all food allergies, which in severe cases may lead to anaphylactic shock. Management of food allergies implies the elimination of the allergen from diet, requiring labeling and traceability throughout the food production process, from raw material to the final product.
Eurofins Technologies, a supplier of test kits and systems for laboratory analyses, announces that its ELISA assay (enzyme-linked immunosorbent assay) for the detection of aflatoxin M1, I’screen AFLA M1 milk, has been granted AOAC Research Institute Performance Tested MethodsSM status (AOAC Cert. No. 072002) for use with raw bovine whole milk, skim milk and powdered milk.
Eurofins Technologies recently launched multiple serological assay solutions to detect antibodies targeted against the Nucleocapsid protein of the novel Coronavirus. Antibody tests can be used to identify individuals who have been previously exposed to the virus and in some cases those who have an active infection. However, simple presence of antibodies in an individual does not guarantee immunity to further infections since only a fraction of antibodies provide the ability to neutralize the virus upon a second contact. Currently, elaborate tests requiring high biological safety measures are required to identify these neutralizing antibodies.